COVID-19 Vaccine Evolution and Beyond

• Published in: Journal of experimental neuroscience Vol. 18; p. 26331055231180543
• Main Authors: Brice, Yardley, Morgan, Larry, Kirmani, Maaida, Kirmani, Maha, Udeh, Mercy C
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2023; Sage Publications Ltd; SAGE Publishing
• Subjects: Antiviral agents; Complications of COVID-19 on Brain Health; Coronaviruses; COVID-19 vaccines; Monoclonal antibodies; Morbidity; Mortality; mRNA; Prophylaxis; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; COVID-19 vaccines; COVID-19 mortality; COVID-19 post-vaccination; and morbidity; infection prevention
• ISSN: 2633-1055; 2633-1055; 1179-0695
• DOI: 10.1177/26331055231180543

In December 2019, a new severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was first reported in China. It would quickly spread and emerge as a COVID-19 pandemic. The illness caused by SARS CoV-2 would fall on a clinical spectrum ranging from asymptomatic, mild to severe respiratory symptoms, ARDS, and death. This led to significant morbidity and mortality further impacting at-risk populations with severe complications. Thus, a concerted worldwide effort to meet the challenges of diagnosing, treating, and preventing COVID-19 led to rapid advances in medicine. Some mitigating methods of masking, social distancing, and frequent handwashing, helped to slow the spread of SARS-CoV-2. Effective therapeutics consisting of antivirals and monoclonal antibodies, plus their use for prophylaxis, contributed to the management of COVID-19. The vaccines from various platforms (mRNA, viral vectors, protein base, and inactivated) contributed to decreased incidence, severity, and overall decreased hospitalizations and mortality. This article aims to review the novel mRNA vaccines (Moderna + Pfizer/BioNTech), viral vector (Janssen& Johnson), and protein base (Novavax), their side effects, and their use as boosters.